Authors

• Elena Schiopu (ORCID: https://orcid.org/0000-0002-1831-5292)
• Joachim Schessl
• Rohit Aggarwal (ORCID: https://orcid.org/0000-0001-7531-8038)
• Christina Charles‐Schoeman (ORCID: https://orcid.org/0000-0002-1768-7019)
• Elisabeth Clodi
• Mazen M. Dimachkie (ORCID: https://orcid.org/0000-0002-7148-989X)
• Zoltán Griger (ORCID: https://orcid.org/0000-0002-1371-7911)
• Zsuzsanna Bata‐Csörgõ (ORCID: https://orcid.org/0000-0002-3732-1743)
• Chester V. Oddis (ORCID: https://orcid.org/0000-0002-9529-3111)
• Jiří Vencovský (ORCID: https://orcid.org/0000-0002-0851-0713)
• Sergey Moiseev
• Todd Levine

Institutions

• University of Debrecen (HU)
• University of California, Los Angeles (US)
• University of Pittsburgh (US)
• Sechenov University (RU)
• Charles University (CZ)
• University of Szeged (HU)
• Augusta University (US)
• Institute of Rheumatology (CZ)
• Octapharma (Austria) (AT)
• University of Kansas Medical Center (US)
• Friedrich Baur Stiftung (DE)
• Phoenix Neurological Associates (US)
• Ludwig-Maximilians-Universität München (DE)

Publication Details

Journal

Lara D. Veeken

Published

2025-02-05

DOI

https://doi.org/10.1093/rheumatology/keaf070

Citations

5

Primary Topic

Inflammatory Myopathies and Dermatomyositis

Type

article

Field-Weighted Citation Impact

6.77

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Teva Pharmaceutical Industries
• Alexion Pharmaceuticals
• Alnylam Pharmaceuticals
• CSL Behring
• Sarepta Therapeutics
• Amicus Therapeutics
• Myositis Association
• Argenx
• Horizon Therapeutics
• Astellas Pharma
• Mitsubishi Tanabe Pharma Corporation
• Grifols
• National Institutes of Health
• Genentech
• EMD Serono
• Sanofi Genzyme
• Spark Therapeutics